<DOC>
	<DOC>NCT00172016</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and tolerability of zoledronic acid in preventing skeletal-related events in patients with prostate cancer</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written informed consent must be obtained Age &gt; 18 years Histologically confirmed diagnosis of carcinoma of the prostate Current (or previous) objective evidence of metastatic disease to the bone Currently receiving 1st line hormonal therapy with LHRH agonists or other hormonal treatments ECOG performance status of 0, 1, or 2 Patients with abnormal renal function as evidenced by either a serum creatinine determination 1.5 x or greater above the upper limit of normal or by a calculated creatinine clearance of 60 ml/minute or less Corrected (adjusted for serum albumin) serum calcium concentration &lt; 8.0 mg/dl (2.00 mmol/L) WBC&lt;3.0x1'000'000'000, ANC &lt; 1500/mm3, Hgb&lt;8.0 g/dL, platelets &lt; 75 x 1'000'000'000/L. Liver function tests &gt;2.5 ULN, serum creatinine &gt;1.5 ULN. Patients with another nonmalignant disease which would confound the evaluation of primary endpoints or prevent the patient complying with the protocol. Known hypersensitivity to zoledronic acid or other bisphosphonates Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study Other protocoldefined inclusion / exclusion criteria apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Zoledronic acid</keyword>
	<keyword>SRE</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>